VYEPTI DIN 02510839
Status: Marketed
Holder: LUNDBECK CANADA INC
Available to quote
Health Canada record
| Active ingredient(s) | EPTINEZUMAB 100 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | N02CD05 EPTINEZUMAB |
|---|
| Original market date | 17-Aug-2022 |
|---|
| Current status date | 17-Aug-2022 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Lundbeck Canada Inc — licence 100814, currently licensed, last inspection rating C (2023-04-11).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing EPTINEZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02542269 | VYEPTI | LUNDBECK CANADA INC | Solution | EPTINEZUMAB 300 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 24987 | 2021-01-11 | New Drug Submission (NDS) | |
Request a quote for VYEPTI
How to read a Canadian DIN record